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The study of Hicks et al. (I) comparing regional myocardial fluoro- 
deoxyglucose and C-II acetate data in male volunteers who re- 
ceived hyperinsulinemic-euglycernic clamping with and without 
lipid emulsion infusion is elegant, well conceived and well executed; 
the results are presented in a straightforward manner. In this letter, 
I make SOme statements and also ask the authors to consider and 
discuss Some hypotheses and facts in relation to cardiac studies with 
F-18 fluorodcoxyglucose and positron emission tomography. 
They report “significant regional variation in glucose metabo- 
lism” and lower glucose utilization, particularly in the septum 
compared with other walls. This finding could not be related to 
myocardial oxidative metabolism as independently measured with 
C-II acetate and was probably independent of regional perfusion. 
They State that F-18 iluorodeoxyglucose “may not perfectly trace 
glucose metabolism. ” Cos~ment: The term “perfectly” appears 
ambiguous. In their study gluco se metabolic rates were assessed 
with F-18 fluorodeoxyglucose and positron emission tomography 
and were expressed as pmollg per min. Thus, the accuracy of such 
metabolic rates as related to oxidative metabolism remains indeter- 
minate. 
They further state that the absolute values of glucose utilization 
derived from Patlak analysis may not be identical with irue exoge- 
nous glucose utilization. Qi/estion: How close are they? 
They suggest that standardization of the metabolic conditions by 
the use of glucose and insulin infusion in individuals undergoing 
positron emission tomography studies with F-18 fluorodeoxyglucose 
will minimize regional inhomogeneity in F-18 Auorodeoxyglucose 
uptake. Comment: F-18 fluorodeoxyglucose and positron emission 
tomography have been recommended for clinical differentiation of 
myocardial viability from scarring on the basis of a study by Tillisch 
et al. (2). That research used a scanner with low spatial resolution 
and without the addition of the glucose-insulin infusion. In retro- 
spect, what was the accuracy of that study for the claims reported? 
The authors state: “Without direct estimation of glucose oxida- 
tion rates. , , .” Comrwnt: The authors are correct in wondering 
about glucose oxidation rates. New users of positron emission 
tomography currently are told that the] should give the patient 
glucola and assume that this induces the heart to consume glucose 
preferentially. However, Wisneski et al. (3) showed that despite a 
significant amount of exogenous glucose administered (wit;1 a con- 
comitant insulin increase! glucose oxidation accounted for only 32% 
of total glucose extracted; SO% of the extracted glucose was 
probably initially synthesized as giycogen. These findings were 
recently confirmed and extended by Saddik and Lopaschuk (4). 
They showed that in rat hearts perfused with I I mM (Z-H-3/U-C-14) 
elucose and low fat perfusate, 14% of the extracted glucose is 
oxidized while 86% of extracted glucose undergoes giyco]ySis. 
Thus, it appears reasonable to conclude that >60% of myocardial 
oxidation under these conditions was derived +om exogenous and 
endogenous paMate metabolism. The authors also demonstrated 
that insulin did not modify exogenous fatty acid metabolism. There- 
fore, under most physiologic conditions except from increased work 
(Can-G et al. [SD, glucose (in the presence or absence of insulin) is 
not the PrimarY source for myocardlal oxidative metabolism. 
Even if F-18 fluorodeoxyglucose measured glucose oxidative 
metabolism, which it does not, substrate selection by the heart 
under almost all circumstances is from exogenous fatty acids and 
from endogenous triglycerides, as well as lactate. Positron emission 
tomography F-18 fluorodeoxyglucose measures only glucose uptake 
and it is inaccurate to use F-18 fluorodeoxyglucose to measure 
giucose metabolic rates (6). 
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Reply 
F-18 luorodeoxyglucose tissue retention and myocardial ghcose 
utilization. We recognize, and acknowledged in tne Discussion 
section of our article, the assumptions and p,ltential inaccuracies 
inherent in the use of the fluorine-18 (F-18) fl<nrodeoxyglucose 
tracer kinetic model for estimating myocardial glucose utilization. 
As Bianco correctly asserts, the retention of F-18 fluorodeoxyglu- 
case within the heart reflects not only the oxidative metabolism of 
glucose but also its incorporation into glycogen and metabolism 
through anaerobic glycolysis. Increased F-18 fluorodeoxyglucose 
uptake by the heart may not necessarily correlate with increased or 
preferential oxidative metabolism of glucose. However, under 
steady state conditions, myocardial F-18 fluorodeoxyglucose reten- 
tion is expected to reflect glycolytic flux, and several animal studies 
under such conditions have documented a close agreement of F-18 
fluorodeoxyglucose-estimated and directly measured glucose utili- 
zation (I ,2). We believe that the cuglycemic-hyperinsulinemic 
clamping as used in our study produces a stable metabolic environ- 
ment in which F-18 fluorodeoxyglucose tissue retention correlates 
with exogenous myocardial glucose utilization. 
The importance of our findings, however, was not in the quan- 
titative evaluation of myocardial glucose utilization a:: such, but in 
the confirmation of regional variations in F-18 fluorodeoxyglucose 
retention (which had previously been observed in qualitative semi- 
quantitative studies (3-5) using quantitative me?hodology. A knowl- 
edge of this variation acd that it can be minimized by strict 
metabolic control has significant implications for the use of F-18 
fluorodeoxyglucose with positron emission tomography to assess 
cardiac disease, as outlined in the study. 
01992 by the American College of Cardiology 
073%lG9?/92/$5.00 
JACC Vol. 20. No. 6 
November 15, 1992:1442-A 
LETTERS PO THE EDITOR 1443 
other groups have also demonstrated the positive predictive value of 
qualitative positron emission tomographic criteria of viability for 
recovery after revascularization and, perhaps more important, the 
negative predicti ower of the absence of such criteria for lack 
recovery f6,7). 
evaluation of viability in the interventri 
di~culties associated with assessing postoperative wall motion in 
the septum after coronary artery bypass surgery as a result of the 
frequent development of paradoxic septal motirln, iitr septum was 
excluded from analysis in the study by Tillisch et al. Therefore, the 
potential problems associated with assessing the signihsance of 
altered F-18 fluo~odeoxygl~cose retention in this region may not 
have been recognized. We have discussed the problems with eval- 
uation of F-IS fluorodeoxyglucose retention in the stptum at greater 
length elsewhere (8). 
Finally, we agree that the use of oral glucose loading in patients 
undergoing positron emission tomography with F-18 fluorodeoxy- 
glucose may not induce the heart to use glucose preferentially. The 
likely mechanism of enhanced F-18 fluorodeoxyglucose image qual- 
ity after glucose administration is enhanced tissue uptake and blood 
clearance of glucose and F-18 fluorodeoxyglucose due to concomi- 
tant insuhn response. Although insulin is not required for myocar- 
dial glucose uptake, its presence does stimulate grucose U+LG 
apparently by increasing transmembrane transport (9). Although the 
use of oral glucose loading to enhance F-18 Wuorodeoxyglucose 
image quality is largely empiric, it provided the first and important 
recognition of the importance of metabolic milieu on F-18 fluorode- 
oxyglucose image quality and offers a reasonably powerful means of 
standardizing metabolic conditions in most patients. We have ex- 
tended the approach to metabolic standardizatron with more sophis- 
ticateo control of metabolic state in the experimental setting (8) and 
more recently in clinical studies (9) by use of glucose infusion (IQ,1 I) 
combined with insulin supplementation. This approach has allowed 
study of diabetic patients, who form an important group of patients 
with coronary artery disease and in whom positron emission tomog 
raphy with F-18 fluorodeoxyglucose has either been precluded or is 
often of suboptimal quality. 
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In the study by Szlachcic et al. (I) on the role of ischemia and left 
ventricular hypertrophy in the genesis of ventricular arI,hythmias, 
we are puzzled by the greater prevalence of ventricular arrhythmias 
in patients previously treated with diuretic drugs. We wonder 
whether the influence of diuretic drugs could be explained by a 
greater left ventricular mass. It is not clear from the 
whether adjustment was ma for the degree of left ventricular 
hypertrophy quantitatively. e have previously shown (2; that 
there is a graded and continuous relatron be!ween the extent of’ left 
ventricuiar hypertrophy and the frequency and complexity of ven- 
tricutar arrhythmias. Therefore, performing such an analysis may 
help to explain the apparent influence of diuretic drugs. 
We note that the authors stated that no previous studies had 
systematically or prospectively attempted to exclude patients with 
underlying ischemic heart disease. In fact, in our study (2), patients 
with coronary artery disease as defined by the presence of ~25% 
reduction in lumen diameter by coronary arteriogram were syste? 
atically and prospectively excluded. 
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